Bang, bang.
From inflammation to pain treatment, RGS, through its Progenza platform, now holds multiple patents in Japan for the use of Mesenchymal Stem Cells.
Then, Sygenus will be added, for the use of stem cells secretions.
Very good news. This will only strengthen Kyocera's commercial position in the Japanese market.
- Forums
- ASX - By Stock
- CMB
- Ann: Regeneus to be granted new patent to target pain in Japan
Ann: Regeneus to be granted new patent to target pain in Japan, page-2
Featured News
Add CMB (ASX) to my watchlist
(20min delay)
|
|||||
Last
41.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.891M |
Open | High | Low | Value | Volume |
41.0¢ | 41.0¢ | 41.0¢ | $121 | 294 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 294 | 41.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.0¢ | 24 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 294 | 0.415 |
2 | 3870 | 0.410 |
1 | 400 | 0.400 |
1 | 6000 | 0.390 |
1 | 5000 | 0.380 |
Price($) | Vol. | No. |
---|---|---|
0.480 | 24 | 1 |
0.500 | 334 | 1 |
0.545 | 400 | 1 |
0.000 | 0 | 0 |
0.000 | 0 | 0 |
Last trade - 10.02am 08/11/2024 (20 minute delay) ? |
Featured News
CMB (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online